Associated response in bone mineral density and atherogenic lipid profile during treatment with two different selective estrogen receptor modulators: levormeloxifene and raloxifene

Abstract

Objective: We recently demonstrated a correlation between the responses in two target areas, bone and lipids, during treatment with hormone replacement therapy. Whether the same association exists during treatment with selective estrogen receptor modulators (SERMs) has not been examined before. Study design: This was an exploratory, post hoc analysis of data from two randomized, double-blind, placebo-controlled trials. Study population: From both studies we examined only the Danish subpopulation. Study 1 included 133 women treated with placebo or levormeloxifene in four different doses for 12 months, and study 2 included 248 women treated with raloxifene in three different doses or placebo for 24 months. Measurements: Bone mineral density (BMD) of the spine and hip was measured semiannually. Serum lipids and biochemical bone markers were determined at each visit. To eliminate interindividual differences, all values were calculated as individual percentage change from baseline. Results: We found a significant correlation between the increase in BMD of the spine and hip and the decrease in total cholesterol and low-density lipoprotein. Conclusion: Our study showed that, in healthy postmenopausal women, the women with the greatest response in BMD were also those with the most favorable response in lipid profile during treatment with SERMs.

• BONE MINERAL DENSITY
• CHOLESTEROL
• LOW-DENSITY LIPOPROTEIN
• BONE MINERAL MARKERS
• SELECTIVE ESTROGEN RECEPTOR MODULATORS
• LEVORMELOXIFENE
• RALOXIFENE